WO2023006860 - SRPK INHIBITORS
National phase entry:
Publication Number
WO/2023/006860
Publication Date
02.02.2023
International Application No.
PCT/EP2022/071160
International Filing Date
28.07.2022
Title **
[English]
SRPK INHIBITORS
[French]
INHIBITEURS DE SRPK
Applicants **
MERCK PATENT GMBH
Inventors
LEIENDECKER, Matthias
HEINRICH, Timo
Priority Data
21188490.3
29.07.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2367 | |
| EPO | Filing, Examination, Granting | 9474 | |
| Japan | Filing, Examination, Granting | 2155 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
23,207
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
and m have the meaning according to the claims, are SRPK inhibitors, and can be used, inter alia, for the treatment of hyperproliferative disorders.[French]
et m ont la signification indiquée dans les revendications, qui sont des inhibiteurs de SRPK, et qui peuvent être utilisés, entre autres, pour le traitement de troubles hyperprolifératifs.